vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v11i1.146vsp-524Research ArticleВ ПОМОЩЬ ВРАЧУA DOCTOR’S AIDСОВРЕМЕННЫЙ ВЗГЛЯД НА ИММУНОМОДУЛИРУЮЩУЮ ТЕРАПИЮMODERN APPROACH TOWARDS IMMUNOMODULATION THERAPYНамазова-БарановаЛ. С.Namazova-BaranovaL. S.namazova@nczd.ruВишневаЕ. А.VishnevaE. A.

Elena Aleksandrovna Vishneva, MD, senior research scientist of the Department of Hospital-replacing technologies, allergologist and immunologist of the Department of Remedial treatment  of Children with hypersensitivity diseases and diseases of the respiratory system of RI of Preventive Pediatrics and Remedial treatment   of SCCH of RAMS

vishneva@nczd.ruНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children’s Health RAMS, Moscow; Sechenov First Moscow Medical UniversityRussian FederationНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children’s Health RAMS, MoscowRussian Federation201215012012111Вопросы современной педиатрии143146Copyright © Намазова-Баранова Л.С., Вишнева Е.А., 20122012Намазова-Баранова Л.С., Вишнева Е.А.Namazova-Baranova L.S., Vishneva E.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/524дендритные клеткииммуномодуляторыпидотимодdendritic cellsimmunostimulantspidotimodReferencesSteinman R. M., Banchereau J. Taking Dendritic Cells into Medicine // Nature. — 2007; 449: 419–426.Steinman R. M., Banchereau J. Taking Dendritic Cells into Medicine // Nature. — 2007; 449: 419–426.Харит С. М., Начарова Е. П., Намазова-Баранова Л. С. и соавт. Эффективность пидотимода для профилактики респира- торных заболеваний у детей // Детские инфекции. — 2010; 4: 32–36.Харит С. М., Начарова Е. П., Намазова-Баранова Л. С. и соавт. Эффективность пидотимода для профилактики респира- торных заболеваний у детей // Детские инфекции. — 2010; 4: 32–36.Sheng К. С., Pietersz G. A., Wright M. D. et al. Dendritic cells: activation and maturation applications for cancer immunotherapy // Curr. Med. Chem. — 2005; 12: 1783–1800.Sheng К. С., Pietersz G. A., Wright M. D. et al. Dendritic cells: activation and maturation applications for cancer immunotherapy // Curr. Med. Chem. — 2005; 12: 1783–1800.Аллергия у детей: от теории к практике / под ред. Л. С. Намазовой-Барановой. — М.: Союз педиатров России, 2010–2011. — 668 с.Аллергия у детей: от теории к практике / под ред. Л. С. Намазовой-Барановой. — М.: Союз педиатров России, 2010–2011. — 668 с.Donnini A., Argentari K., Mancini R. et al. Phenotype, antigenpresenting capacity, and migration of antigen-presenting cells in young and old age // Exp. Gerontol. — 2002; 37: 1097–1112.Donnini A., Argentari K., Mancini R. et al. Phenotype, antigenpresenting capacity, and migration of antigen-presenting cells in young and old age // Exp. Gerontol. — 2002; 37: 1097–1112.Rharbaoui F., Drabner B., Borsutzky S. et al. The mycoplasmaderived lipopeptide MALP-2 is a potent mucosal adjuvant // Eur. J. Immunol. — 2002; 32: 2857–2865.Rharbaoui F., Drabner B., Borsutzky S. et al. The mycoplasmaderived lipopeptide MALP-2 is a potent mucosal adjuvant // Eur. J. Immunol. — 2002; 32: 2857–2865.Fiorentini S., Becker P. D., Marini E. et al. HIV-1 matrix protein pl7 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens // Viral. Immunol. — 2006; 19: 77–88.Fiorentini S., Becker P. D., Marini E. et al. HIV-1 matrix protein pl7 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens // Viral. Immunol. — 2006; 19: 77–88.Riboldi P., Gerosa M., Meroni P. L. Pidotimod: a reappraisal // Int. J. Immunopathol. Pharmacol. — 2009; 22 (2): 255–262.Riboldi P., Gerosa M., Meroni P. L. Pidotimod: a reappraisal // Int. J. Immunopathol. Pharmacol. — 2009; 22 (2): 255–262.Marelli P., Lupetti A., Senesi S. et al. Potenziamento della resistenza alle infezioni virali e batteriche dopo somministrazione di Pidotimod nel topo // Drugs. Exp. Clin. Res. — 1993; 19: 15–21.Marelli P., Lupetti A., Senesi S. et al. Potenziamento della resistenza alle infezioni virali e batteriche dopo somministrazione di Pidotimod nel topo // Drugs. Exp. Clin. Res. — 1993; 19: 15–21.Careddu P., Biolchini A., Alfano S., Zavattini G. Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood // Adv. Otorhinolaryngol. — 1992; 47: 328–331.Careddu P., Biolchini A., Alfano S., Zavattini G. Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood // Adv. Otorhinolaryngol. — 1992; 47: 328–331.Careddu P. Role of immunoactivation with pidotimod in recurrent respiratory infections in childhood // Drug. Res. — 1994; 44: 1506–1511.Careddu P. Role of immunoactivation with pidotimod in recurrent respiratory infections in childhood // Drug. Res. — 1994; 44: 1506–1511.Aivazis V., Hatzimichail A., Papachristou A. et al. Clinical evaluation and changes of the respiratory epithelium function after administration of pidotimod in Greek children with recurrent respiratory tract infections // Minerva Pediatr. — 2002; 54: 315–319.Aivazis V., Hatzimichail A., Papachristou A. et al. Clinical evaluation and changes of the respiratory epithelium function after administration of pidotimod in Greek children with recurrent respiratory tract infections // Minerva Pediatr. — 2002; 54: 315–319.Giagulli C., Noerder M., Avolio M. et al. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level // Int. Immunopharmacol. — 2009; 9 (12): 1366–1373.Giagulli C., Noerder M., Avolio M. et al. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level // Int. Immunopharmacol. — 2009; 9 (12): 1366–1373.

The authors declare that there are no conflicts of interest present.